Multivalent Inactivated Vaccine Protects Chickens from Distinct Clades of Highly Pathogenic Avian Influenza Subtypes H5N1 and H5N8
Open Access
Abstract
Background/Objective: Highly pathogenic avian influenza (HPAI) H5 subtype remains a significant menace to both the poultry industry and human public health. Biosecurity and mass vaccination of susceptible commercial poultry flocks are crucial to reduce the devastating economic loss and hinder the evolution of the virus. Methods: In this study, we developed a multivalent avian influenza virus (AIV) vaccine, including strains representing the HPAI 2.2.1.1., 2.2.1.2., and 2.3.4.4b clades circulating in Egypt and the Middle East. Specific pathogen-free (SPF) two-week-old chickens were vaccinated with a single vaccine shot and observed for four weeks post-vaccination before being challenged. The challenge experiment involved using one strain of HPAI H5N1 subtype clade 2.2.1.2 and two strains of HPAI H5N8 subtype clade 2.3.4.4b derived from chickens and ducks. To assess the vaccine’s potency and efficacy, the pre-challenge humoral immune response and post-challenge survival and virus shedding were evaluated. Results: All the vaccinated birds exhibited 100% seroconversion 2 weeks post-vaccination (2 WPV). In addition, protective antibody titers against each diagnostic antigen, i.e., 7.8 ± 1.8 (H5N1, clade 2.2.1.2), 10.0 ± 0.0 (H5N1, clade 2.2.1.1), and 7.5 ± 0.9 (H5N8, clade 2.3.4.4b) were detected 3 WPV. The vaccination achieved complete protection (100%) against all challenge viruses with no disease symptoms. The vaccinated birds exhibited a statistically significant reduction in oropharyngeal virus shedding 2 days post-challenge (DPC). Conclusions: This study illustrated that a single application of a multivalent genetic-matching whole AIV vaccine under laboratory conditions elicits adequate protection against the HPAI challenge, representing 2.2.1.2 and 2.3.4.4b clades. The developed vaccine has the potential to be a vaccine of choice against a broad range of HPAI in commercial flocks raised under field conditions in endemic areas.Keywords
Funding Information
- Reference Laboratory for Veterinary Quality Control on Poultry Production (RLQP), Animal Health Research Institute (AHRI)
- MEVAC—Middle East for Vaccines, Egypt
This publication has 55 references indexed in Scilit:
- Prediction of highly pathogenic avian influenza vaccine efficacy in chickens by comparison of in vitro and in vivo data: A meta-analysis and systematic reviewVaccine, 2023
- Genetic and biological characteristics of the globally circulating H5N8 avian influenza viruses and the protective efficacy offered by the poultry vaccine currently used in ChinaScience China Life Sciences, 2021
- A single dose of inactivated oil-emulsion bivalent H5N8/H5N1 vaccine protects chickens against the lethal challenge of both highly pathogenic avian influenza virusesComparative Immunology, Microbiology and Infectious Diseases, 2021
- Laboratory Methods for Assessing and Licensing Influenza Vaccines for Poultry2020
- Influenza2019
- Vaccination of poultry successfully eliminated human infection with H7N9 virus in ChinaScience China Life Sciences, 2018
- Vaccines and vaccination for avian influenza in poultry2016
- Evolutionary features of influenza A/H5N1 virus populations in Egypt: poultry and human health implicationsArchives of Virology, 2016
- Avian Influenza Virus Isolation, Propagation, and Titration in Embryonated Chicken Eggs2014
- Pathogenicity of H5 influenza viruses for ducksArchives of Virology, 2005